Single-Cell Analysis Market Size to Hit USD 15.28 Billion by 2030

According to Nova one advisor, the global Single-Cell Analysis market was valued at USD 3.30 billion in 2021 and it is expected to hit around USD 15.28 billion by 2030 with a CAGR of 18.9% during the forecast period 2022 to 2030.

Get the Sample Copy of Report@ https://www.novaoneadvisor.com/report/sample/6786

Key Takeaways:

• By Product, the U.S. Single-cell Analysis market was valued at USD 890 million in 2021 and expected to witness growth at a CAGR of 10.2% from 2022 to 2030.
• By product, the consumables segment held the largest revenue share in 2021. The segment is anticipated to be driven by the extensive use of consumables in genetic research, exosome analysis, and RNA and DNA isolation
• Based on application, the cancer segment captured the largest revenue share in 2021. The segment is being driven by single-cell analysis, which has shown to be successful for earlier cancer diagnoses. These techniques make it simple to determine cell kinds, mutation rates, and growth settings
• In terms of workflow, the single cell isolation and library preparation segment held the largest revenue share in 2021. Increasing research using single-cell analysis is anticipated to boost the revenue growth
• On the basis of end-user, the academic and research laboratories segment held the largest revenue share in 2021. The widespread use of different SEA techniques in research settings has been influenced by a sizeable number of ongoing research projects at academic institutions that use SEA assays
• North America held the largest revenue share in 2021. This is mostly attributed to the occurrence of significant market participants and rising R&D spending and federal assistance
• Asia Pacific is expected to grow at the highest rate over the forecast period owing to factors such as the increasing prevalence of target diseases, growing aging population, and rising single cell technology adoption

Technology advances, expanding applications in cancer research, and higher government funding for cell-based research are the main drivers of the market. In addition, the market is advancing as a result of the COVID-19 pandemic. For instance, in January 2021, according to the American Journal of Physiology, variations in the peripheral blood mononuclear cellular profiles of COVID-19-infected patients were examined by using single-cell analysis (SEA) through mass cytometry, which supplemented the industry growth.

Government agencies around the world have increased funding for vaccine development and production in response to the ongoing pandemic's economic and social costs, which has increased the use of SEA tools for COVID-19 research. In order to develop better prognostic and diagnostic indicators and establish suitable therapeutic approaches for people with serious disease presentation, it is essential to know the host immune response throughout pathogenicity. Therefore, the market is positively impacted by COVID-19 because single-cell analysis helps in the assessment of peripheral immune function in the disease and makes new contributions to the study of the disease's pathophysiology and treatment possibilities.

Single-cell technology aids in the molecular level examination of pathways and processes as well as the assessment of cellular heterogeneity. This technology is developing rapidly with uses in oncology, immunology, and other fields. Further, the development of sophisticated tools that make transcriptomic and proteomic processes simpler is boosting the use of SEA methods. Researchers are now able to comprehensively examine previously unstudied uncommon cell types owing to developments in scRNA sequencing (scRNAseq). The application of single-cell genomic/transcriptomic analysis in the biomedical area has been greatly expanded by the development of microfluidics technology. Furthermore, cell dissociation and tissue digestion have been adapted for a large range of microfluidic devices, which have increased the adoption of SEA technology and further boosted industry growth.

The rising investment flow in R&D in this space is reflected in the rising number of research publications. For instance, in April 2020, A USD 2 million funding round was headed by the venture capital firm i&i Biotech Fund for Sampling Human, a young life science technology startup that has created a diagnostic platform that uses genetically modified cells to examine other cells in their environment (i&i Bio). Further, R&D and business growth will all be advanced by the investment. Moreover, these expenditures indicate a better growth opportunity for this market because R&D efforts serve as the foundation for innovation. Additionally, scientists are analyzing geographic variability in gene expression profiles at the single-cell level, which is expected to increase the demand for consumables and equipment for analysis, thus propelling the industry's growth.

Immediate Delivery Available | Buy this Premium Research Report@ https://www.novaoneadvisor.com/report/checkout/6786

Report Scope of the Single-cell Analysis Market

 Product Insights

The consumables segment held the largest revenue share of over 50.2% in 2021 and is projected to exhibit a significant CAGR from 2022 to 2030 owing to the high usability of isolation products, large-scale adoption of cell sorting beads, frequent purchase of buffers and reagents, and growing demand for assay kits. Increase in the prevalence of target diseases and constant need for consumables required for the assays during scientific activities are propelling the segment growth. Moreover, the extensive use of consumables such as reagents throughout SCA assays creates a continuous high demand for these products. These reagents are available in different forms including probes, cellular markers, multicolor cocktails, and even phenotyping agents. The robust activities of scientific entities have resulted in the massive adoption and purchase of reagents, thus leading to revenue generation in the global market.

The installation of new instruments, replacement of old instruments, and services related to instruments led to revenue generation for the instruments segment. Owing to the high-end features and the technically advanced analytical options, the automated instruments are anticipated to witness significant growth during the forecast period.

Application Insights

The cancer segment captured the largest revenue share of over 30.5% in 2021. Single-cell analysis has proved to be effective for the diagnosis of cancer cells. The genetic variation via cell proliferation conditions, mutation rates, and cell types can be easily identified using these techniques. As per the American Cancer Society, cancer is the second most common cause of death in the U.S. after heart disease. According to cancer statistics, in 2022, 1.9 million new cancer cases are expected to occur in the U.S. Thus, increasing prevalence of cancer and the never-ceasing studies and developments in this field are anticipated to positively impact the industry growth.

The existence of a significant number of research activities for evaluating single-cell genomics and proteomics has led to the increasing implementation of SCA methods in therapeutic and diagnostics applications. Moreover, increasing demand for stem cell therapies for regenerative and personalized medicines is bolstering this market space. Therapies like regeneration of hair, transplants of tissue, and organ and bone marrow are boosting the usage rates of single-cell analysis techniques.

Workflow Insights

In 2021, the single cell isolation and library preparation segment accounted for the largest revenue share of over 35.0%. The vast range of applications for SCA has subsequently increased the demand for cell isolation and library preparation products such as kits and reagents. In addition, a substantial number of industry players are offering a range of products for single-cell isolation, to name a few, FACS and MACS for heterogeneous cell suspensions, microdissection of fixed tissue samples, flow cytometry, and microfluidics, in this segment, in turn, augmenting the revenue growth.

The downstream analysis segment is gaining traction owing to the technological advancements over the past few years. Technologies such as the emergence of next-generation sequencing for analyzing cellular expressions, mass spectrometry, and FISH (Fluorescence in situ hybridization) have proven to be important tools for SCA. Also, the market is witnessing the increasing automation of machines and artificial intelligence for data analysis. Several software and computational methods have been developed and are being employed due to their benefits such as scalability, flexibility, and high success rates. For example, as of 2021, there were over 1000 single-cell RNA analysis tools. Thus, this high growth of database tools reflects the interest and availability of SCA technologies, which, in turn, will spur the industry growth in the near future.

End-user Insights

The academic and research laboratories accounted for the largest revenue share of over 70.2% in 2021 due to the wide use of single-cell analysis technology in research settings. The considerable number of ongoing scientific projects at various universities employing SCA techniques has driven its adoption in 2021. The introduction of spatial genomics accelerates the single-cell analysis in research activities, which is another key factor driving the segment. Furthermore, developing new tools to tackle the research limitation is driving the market, for example, researchers at Stony Brook University, New York developed a new biomedical research tool, single-cell cyclic multiplex in situ tagging (CycMIST) technology in June 2022. This technology enables scientists to assess functional proteins in a single-cell and contribute to the diagnostic and discovery fields.

Technological progressions such as the use of microfluidics for the development of cell and gene therapies have increased the adoption of SCA by biotechnology and pharmaceutical companies. Moreover, increasing penetration of multi-omics in drug development research would further drive the market. A substantial number of firms have invested in genomics to have an access to various genomics databases. For instance, Lifebit, a U.K.-based big data company, announced partnering with Boehringer Ingelheim in March 2022. The partnership will make use of the Cloud OS of Lifebit, the first federated platform for genomics to build a data analytics infrastructure for Boehringer. This infrastructure will capture disease insights from biobanks for the development of medicines. Boehringer was also associated with Lifebit’s REAL platform in 2021 to accelerate the detection and tracking of disease outbreaks.

Regional Insights

North America dominated the global market with a revenue share of over 35.4% in 2021. This can be attributed to factors such as multiple government funding programs, rising awareness regarding personal healthcare and related expenditure, faster adoption of novel analytical tools and techniques, and the availability of trained personnel. The U.S. is a major contributor to the industry growth in North America. For example, the U.S. NIH (National Institutes of Health) through its Common Fund Programs is supporting metabolomics research. Formerly, the NIH had also supported the single cell analysis program (SCAP) through the same funds. Extraordinary healthcare infrastructure, demand for personalized medicines, and the presence of key market players are some of the key factors fueling the regional growth.

Asia Pacific is expected to exhibit the fastest CAGR over the forecast period. In the past years, the growing medical industry, rapidly developing healthcare systems, and increasing geriatric population have resulted in fueling the demand for cutting-edge diagnostic tools in the emerging economies of Asia Pacific. The focused efforts and outsourcing in this region have led to significant growth.

Key Companies & Market Share Insights

The market for single cell analysis has been endlessly growing over the past few years owing to the increasing upswing of single cell analysis techniques for therapeutic and diagnostic applications. The prevalence of genetic disorders has resulted in the increasing need for early diagnosis and better treatments. This has created worthwhile opportunities for emerging players to capture untapped opportunities. These emerging companies have focused on the development of innovative and technologically advanced products to fulfill consumer demand. For instance, in February 2021, SeqWell Inc. announced the launch of the plexWell Single Cell Rapid Kit. The kit can be used for single-cell RNA sequencing and simplified preparation of NGS libraries. Further, the company has signed a distribution agreement with CELLINK AB in February 2021 for the commercialization of its products to expand its presence outside the U.S.

Developed and matured market players are expanding their market presence and product portfolios by acquisitions and partnership business models. For example, in January 2022, BD Biosciences, a part of Becton, Dickinson & Company, acquired CytognosS.L., a Spain-based biotech company that offers flow cytometry solutions. This acquisition has helped BD expand its flow cytometry portfolio for cancer diagnostics and clinical research. Such company initiatives are expected to intensify market competition. Some prominent players in the global single cell analysis market include:

• Thermo Fisher Scientific, Inc.
• QIAGEN NV
• Bio-Rad Laboratories Inc.
• Illumina Inc.
• Merck KGaA
• Becton, Dickinson & Company
• Fluidigm Corporation
• 10x Genomics, Inc.
• BGI
• Novogene Corporation

Segments Covered in the Report

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2017 to 2030. For this study, Nova one advisor, Inc. has segmented the global Single-cell Analysis market

• Product
  • Consumables
    • Reagents
    • Assay Kits
  • Instruments
    • Manual Instruments
    • Microscopes
    • Hemocytometers
    • Automated Instruments
    • Flow Cytometers
    • Next Generation Sequencing
    • PCR Systems
    • High-content Screening System
    • Cell Microarrays
    • Automated Cell Counters
• Application
  • Cancer
  • Immunology
  • Neurology
  • Stem Cell
  • Non-invasive Prenatal Diagnosis
  • In-vitro Fertilization
  • Others
• Workflow
  • Single Cell Isolation & Library Preparation
  • Downstream Analysis
  • Data Analysis
• End-user
  • Academic & Research Laboratories
  • Biotechnology & Pharmaceutical Companies
  • Hospitals & Diagnostic Laboratories
  • Others

Report Objectives

• To define, describe, and forecast the global Single-Cell Analysis market based on product, technique, methodology, category, and region
• To provide detailed information regarding the major factors influencing the market growth (drivers, restraints, growth opportunities, and challenges)
• To strategically analyze micromarkets1 with respect to individual growth trends, future prospects, and contributions to the overall market
• To analyze the opportunities in the market for key stakeholders and provide details of the competitive landscape for major market leaders
• To forecast the size of the market segments with respect to five main regions—North America (the US and Canada), Europe (Germany, the UK, France, Italy, Spain, and Rest of Europe), Asia Pacific (Japan, China, India, Australia, South Korea, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and the Middle East and Africa
• To profile the key market players and comprehensively analyze their market shares and core competencies2
• To track and analyze competitive developments such as mergers and acquisitions, new product developments, partnerships, agreements, collaborations, and expansions in the global Single-Cell Analysis market

For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/6786

About Us

Nova One Advisor is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Nova One Advisor has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings.

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333